DCF Advisers’s AstraZeneca AZN Stock Holding History

DCF Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.13M	Sell	5,750 -16,400	-74%	-$3.16M	0.3%	56
2025 Q4	$4.07M	Buy	+22,150	New	+$3.88M	1.09%	28
2025 Q3	–	Sell	-22,900	Closed	-$3.2M	–	98
2025 Q2	$3.2M	Hold	22,900	–	–	1.48%	23
2025 Q1	$3.37M	Buy	+22,900	New	+$3.31M	1.61%	21
2022 Q1	–	Sell	-6,373	Closed	-$742K	–	71
2021 Q4	$742K	Hold	6,373	–	–	0.3%	52
2021 Q3	$765K	Buy	+6,373	New	+$742K	0.34%	53

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

DCF Advisers's AZN Position: Q1 2026 in Review

DCF Advisers reduced its AstraZeneca (AZN) stake by 74% in Q1 2026, selling an estimated $3.16M and leaving 5,750 shares worth $1.13M. The position accounts for 0.3% of the portfolio, ranked #56.

DCF Advisers first reported a position in AZN in Q3 2021 and has held it in 6 quarters since. The position peaked at $4.07M in Q4 2025. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

DCF Advisers held 5,750 shares of AstraZeneca worth $1.13M as of Q1 2026.
DCF Advisers sold 16,400 AstraZeneca shares in Q1 2026, an estimated $3.16M.
AstraZeneca made up 0.3% of DCF Advisers's portfolio in Q1 2026, its #56 holding.
DCF Advisers first reported a position in AstraZeneca in Q3 2021 and has held it in 6 quarters since.
DCF Advisers's AstraZeneca position peaked at $4.07M in Q4 2025.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.